Boardroom Alpha
Start trial
10-Q primary document
ALLO · Quarterly Report (Form 10-Q) · Filed August 12, 2026

Allogene Therapeutics Inc — 10-Q exhibit

allo-20260630xex105.htm
Allogene Therapeutics Inc on Boardroom Alpha
Document


Exhibit 10.5
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED BECAUSE THE REGISTRANT HAS DETERMINED THE INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.



FIRST AMENDMENT
to
THE AMENDED AND RESTATED STRATEGIC COLLABORATION AGREEMENT
This First Amendment to the Amended and Restated Strategic Collaboration Agreement (“First Amendment to ARSCA”) is effective as of 05 August 2025 (the “First Amendment to ARSCA Effective Date”) by and between Foresight Diagnostics, Inc., having a principal place of business at 2865 Wilderness Place, Boulder, CO 80301 (“Foresight”), and Allogene Therapeutics, Inc., having a principal place of business at 210 East Grand Avenue, South San Francisco, CA 94080 (“Company”) and amends the Strategic Collaboration Agreement the Parties entered into as of January 3, 2024. Foresight and Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
RECITALS:
WHEREAS, Company plans to expand the countries where its ALPHA3 Clinical Study may be undertaken and the Parties want to plan for clinical trial readiness by adding an additional Workplan 2.
NOW THEREFORE, for good and valuable consideration, the Parties agree as follows:
1)Workplan 2 shall be added into Exhibit A.

2)Any capitalized terms not otherwise defined herein shall have the meaning set forth in the Strategic Collaboration Agreement as amended.

3)The Strategic Collaboration Agreement, as amended forms the entire understanding between the Parties. Except as expressly amended by this First Amendment to the ARSCA, all other terms and conditions of the Strategic Collaboration Agreement shall remain in full force and effect as entered into.

The Parties have caused this First Amendment to the ARSCA, to be executed by their duly authorized representatives.


FORESIGHT DIAGNOSTICS, INC.    ALLOGENE THERAPEUTICS, INC.
BY:    /s/ John Truesdell    BY: /s/ Dan Hunt
NAME: John Truesdell    NAME: Dan Hunt
TITLE: Chief Business Officer    TITLE: VP, Corp & Business Development
DATE: 21/11/2025    DATE: 13/11/2025



Exhibit 10.5


EXHIBIT A

[***]
[***]
I. [***]    
[***]
a.[***]
b.[***]
c.[***]
d.[***]
e.[***]
f.[***]
II. [***]
[***]
III. Costs
a. The standard fee shall be $35,000 USD and, if additional activities listed in Section 1 are required, the JSC shall agree on the amount of an additional fee to be paid by Company to Foresight not to exceed $200,000. [***]
b. [***]
IV. [***]
[***]

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer